tiprankstipranks
Trending News
More News >
Century Therapeutics (IPSC)
NASDAQ:IPSC
US Market

Century Therapeutics (IPSC) AI Stock Analysis

Compare
192 Followers

Top Page

IP

Century Therapeutics

(NASDAQ:IPSC)

Rating:50Neutral
Price Target:
$0.50
▼(-19.35%Downside)
Century Therapeutics is in a high-growth phase with strong revenue increases but faces profitability challenges. The technical indicators show a slightly bullish trend, while valuation remains difficult due to ongoing losses. The workforce reduction raises concerns, though recent financial results and analyst sentiment provide some optimism.
Positive Factors
Clinical Trials
Century Therapeutics is confident it should have a substantial update due to the momentum for CNTY-101 since dosing its first patient.
Financial Strategy
Century expects its end-2024 cash position to provide an operational runway into 4Q26, which should be sufficient to generate meaningful clinical data for CNTY-101 in the autoimmune setting.
Innovative Therapies
Analyst views the early preclinical data from the αβ iT platform as intriguing and believes clinical proof of concept from a functional iPSC-derived αβ iT candidate could be transformational for the company and the broader cell therapy space.
Negative Factors
Cash Runway
Century's cash runway is only into the fourth quarter of the following year, which could limit investment in the company's innovative platform.
Financial Performance
The price target for Century Therapeutics was reduced due to a decrease in the peer group valuation component.
Program Discontinuation
Century announced the discontinuation of its lead program, CNTY-101 in B cell lymphomas due to the emerging clinical data not meeting the company’s threshold to be considered transformational.

Century Therapeutics (IPSC) vs. SPDR S&P 500 ETF (SPY)

Century Therapeutics Business Overview & Revenue Model

Company DescriptionCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
How the Company Makes MoneyCentury Therapeutics generates revenue through the development and commercialization of its proprietary cell therapy products. The company primarily focuses on clinical-stage therapies, which involve significant research and development investments. Revenue streams may include licensing agreements, partnerships with pharmaceutical companies, and potential future sales of approved therapies. Additionally, strategic collaborations with other biotech companies or institutions can provide funding and shared resources, contributing to Century Therapeutics' earnings. As the therapies advance through clinical trials and gain regulatory approval, commercial sales are expected to become a significant revenue source.

Century Therapeutics Financial Statement Overview

Summary
Century Therapeutics shows strong revenue growth but is still unprofitable with negative net profit margins. The balance sheet is robust with high equity and cash reserves, but operational inefficiencies are a concern, as highlighted by negative free cash flow.
Income Statement
40
Negative
Century Therapeutics has demonstrated significant revenue growth from 2020 to TTM with a notable increase in total revenue to $114.9M in TTM. However, the company is still operating at a net loss, with a TTM net profit margin of -19.10%. The gross profit margin is strong at 100% due to the absence of cost of sales, but the negative EBIT and EBITDA margins indicate operational inefficiencies and high fixed costs.
Balance Sheet
45
Neutral
The balance sheet reveals a reasonable equity ratio of 76.2% in TTM, indicating reliance on equity rather than debt. However, the debt-to-equity ratio has increased slightly over time, standing at 0.20 in TTM. The company has maintained a healthy cash position, which provides some buffer against ongoing losses.
Cash Flow
35
Negative
Cash flow analysis shows negative free cash flow in TTM, with significant cash outflows from operations. The operating cash flow to net income ratio is negative, indicating cash burn. There is a positive free cash flow to net income ratio, yet it is due to the large net loss rather than operational efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue114.90M6.59M2.23M5.20M0.000.00
Gross Profit114.90M6.59M2.23M-4.87M-4.58M-1.75M
EBITDA-9.24M-111.47M-121.21M-119.34M-89.92M-51.44M
Net Income-21.95M-126.57M-136.67M-130.93M-95.82M-54.66M
Balance Sheet
Total Assets315.61M353.22M360.69M486.54M437.38M106.78M
Cash, Cash Equivalents and Short-Term Investments165.12M189.29M172.74M315.50M222.88M75.75M
Total Debt47.79M53.83M48.17M49.41M23.46M21.55M
Total Liabilities75.17M191.85M175.94M183.81M41.14M213.19M
Stockholders Equity240.44M161.36M184.75M302.74M396.24M-106.41M
Cash Flow
Free Cash Flow-114.13M-110.29M-102.08M-16.55M-133.97M-51.09M
Operating Cash Flow-114.51M-110.14M-88.35M14.05M-89.00M-41.27M
Investing Cash Flow63.87M47.48M61.13M-13.13M-298.34M-22.76M
Financing Cash Flow56.49M74.56M-9.72M27.16M417.77M47.69M

Century Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.62
Price Trends
50DMA
0.56
Positive
100DMA
0.57
Positive
200DMA
0.91
Negative
Market Momentum
MACD
<0.01
Negative
RSI
60.65
Neutral
STOCH
58.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 0.62 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.56, and below the 200-day MA of 0.91, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.65 is Neutral, neither overbought nor oversold. The STOCH value of 58.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.

Century Therapeutics Risk Analysis

Century Therapeutics disclosed 90 risk factors in its most recent earnings report. Century Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Century Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$53.65M-59.49%21.15%46.44%
50
Neutral
$48.46M-10.49%8286.79%87.23%
49
Neutral
AU$2.52B3.19-57.47%2.78%36.73%13.67%
47
Neutral
$45.26M-232.51%138.11%76.60%
44
Neutral
$26.91M-83.73%42.39%
42
Neutral
$38.77M-71.90%69.65%27.98%
35
Underperform
$45.37M-101.34%21.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IPSC
Century Therapeutics
0.62
-1.96
-75.97%
PASG
Passage Bio
0.44
-0.47
-51.65%
CELU
Celularity
2.12
-0.77
-26.64%
JSPR
Jasper Therapeutics
3.68
-16.37
-81.65%
STTK
Shattuck Labs
0.82
-3.23
-79.75%
KRON
Kronos Bio
0.88
-0.39
-30.71%

Century Therapeutics Corporate Events

Business Operations and Strategy
Century Therapeutics Announces Major Workforce Reduction
Negative
Jul 7, 2025

On July 1, 2025, Century Therapeutics‘ Board of Directors approved a significant reduction in force, cutting approximately 51% of its workforce to concentrate on high-potential programs. The company anticipates incurring around $3.7 million in severance and related costs, with the reduction expected to be largely completed by the end of the third quarter of 2025.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Century Therapeutics Holds 2025 Annual Stockholders Meeting
Neutral
Jun 16, 2025

On June 12, 2025, Century Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, Daphne Quimi and Carlo Rizzuto, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP’s appointment as the company’s independent registered public accounting firm for the 2025 fiscal year was ratified. These decisions reflect the company’s ongoing efforts to strengthen its governance and ensure financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Century Therapeutics Reports Strong Q1 2025 Financial Results
Positive
May 15, 2025

On May 15, 2025, Century Therapeutics reported its first-quarter financial results and provided a business update. The company initiated patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in the U.S., with plans to expand to Europe. Century is also preparing to start IND-enabling studies for CNTY-308 in mid-2025. Financially, the company reported a net income of $76.6 million for the quarter, significantly up from a net loss in the same period last year, largely due to collaboration revenue from a terminated agreement with Bristol-Myers Squibb.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025